1
|
Koreth J, Kean L, Chinn L, Acevedo LM, Bandman O, Rothman J, Connelly S, Thomas D, Cutler C. PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE. Hemasphere 2022. [PMCID: PMC9431612 DOI: 10.1097/01.hs9.0000851612.99253.8a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
2
|
Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, Mcgregor A, Toth B, Rae J, Hwang O, Lokku A, Miranda P, De Souza V, Jaller-Raad J, Maura Fernandes A, Garcia Salinas R, Chinn L, Townsend MJ, Morimoto A, Tuckwell K. OP0233 EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON’S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2949] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases.Objectives:This was a randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety, and pharmacodynamic effects of FEN in patients with moderate-to-severe systemic lupus erythematosus (SLE) activity.Methods:Patients who met SLICC or revised ACR SLE criteria, had ≥1 serologic marker of SLE, SLEDAI ≥8, and were on ≥1 standard of care (SOC) therapy were included; patients with renal or CNS involvement, or exposure to B cell depleting or calcineurin inhibitor therapy were excluded. Patients were randomized to placebo (PBO), FEN 150 mg QD, or FEN 200 mg BID, for 48 weeks. A corticosteroid taper was recommended, with burst and taper permitted from Week 0 (W0) to W12 and W24 to W36. The primary endpoint was SRI-4 at W48. Post hoc subgroup analyses were conducted based on patient baseline disease characteristics.Results:This study enrolled 260 patients, with the majority recruited in Latin America, USA, and Western Europe. At W48, the SRI-4 response rates for FEN 150 mg QD and FEN 200 mg BID were 51% (95% CI: -8.5, 21.2; p value 0.37) and 52% (95% CI: -7.3, 22.4; p value 0.34), respectively, compared to 44% for PBO (Table 1). Post-hoc analysis showed larger responses in subgroups of patients with higher baseline disease activity (Table 1). Safety results were similar between FEN and PBO arms, although more serious adverse events were observed in the FEN 200 mg BID arm. Study discontinuations were balanced across the 3 arms (24-26%). FEN treatment significantly reduced levels of CD19+ B cells, anti-dsDNA autoantibodies, IgG, and a BTK-dependent RNA signature highly expressed in plasmablasts by W48 compared to PBO; C4 levels modestly improved with FEN vs. PBO (Table 2).Table 1.SRI-4 Response (%) at W48 in Primary Analysis and in Post-hoc Patient SubgroupsPBOFEN 150 mg QDFEN 200 mg BIDSRI-4 Response (%) at W4844n=8451n=8752n=88SRI-4 Response (%) in Baseline Subgroups At least 1 BILAG A48n=4254n=3959n=46 At least 1 BILAG A and SLEDAI increased DNA binding37n=1953n=1765n=26 SLEDAI arthritis with at least 4 swollen joints39n=5750n=5457n=54 SLEDAI arthritis with at least 4 tender joints39n=7153n=7059n=69 CLASI >=1021n=1436n=1131n=16Table 2.Key Biomarker ResultsPBOFEN 150 mg QDFEN 200 mg BIDMedian (%) Change from Baseline at W48 Plasmablast signature-19.7%n=52-54.3%*n=53-51.7%*n=57 CD19+B cells (cells/µl)-0.50n=38-57.0*n=49-57.5*n=48 Anti-dsDNA#(IU/ml)+6.9n=31-38.3*n=36-75.7*n=33 Total IgG (g/L)-0.20n=65-1.25*n=64-1.56*n=64 C3 (g/L)-0.02n=65+0.01n=67-0.01n=66 C4 (g/L)0.00n=65+0.02*n=67+0.01*n=66#Patients who were positive at baseline (>30 IU/mL)*Denotes significant vs. PBO; Kruskal-Wallis false-discovery rate controlled two sided (p-value ≤0.05)Conclusion:The primary endpoint of SRI-4 for FEN was not met despite evidence of strong BTK target and pathway inhibition. FEN had an acceptable safety profile. Several disease activity subgroups were suggestive of a greater treatment effect on SRI-4 compared to PBODisclosure of Interests:David Isenberg Consultant of: Study Investigator and Consultant to Genentech, Richard Furie Grant/research support from: AstraZeneca, Biogen, Consultant of: AstraZeneca, Biogen, Nicholas S. Jones Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Pascal Guibord Shareholder of: Roche, Employee of: Roche, Joshua Galanter Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Chin Lee Shareholder of: Genentech/Roche and Eli Lilly, Employee of: Genentech/Roche, Anna McGregor Employee of: Genentech/Roche, Balazs Toth Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Julie Rae Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Olivia Hwang Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Armend Lokku Shareholder of: Roche, Employee of: Roche, Pedro Miranda Consultant of: Study Investigator for Genentech, Viviane de Souza Consultant of: Study investigator for Genentech, Juan Jaller-Raad Consultant of: Study investigator for Genentech, Anna Maura Fernandes Consultant of: Study investigator for Genentech, Rodrigo Garcia Salinas Consultant of: Study investigator for Genentech, Leslie Chinn Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Michael J. Townsend Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Alyssa Morimoto Shareholder of: Genentech/Roche, Employee of: Genentech/Roche, Katie Tuckwell Shareholder of: Genentech/Roche, Employee of: Genentech/Roche
Collapse
|
4
|
Kim SY, Theunissen JW, Balibalos J, Liao-Chan S, Babcock MC, Wong T, Cairns B, Gonzalez D, van der Horst EH, Perez M, Levashova Z, Chinn L, D'Alessio JA, Flory M, Bermudez A, Jackson DY, Ha E, Monteon J, Bruhns MF, Chen G, Migone TS. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood Cancer J 2015; 5:e316. [PMID: 26024286 PMCID: PMC4476018 DOI: 10.1038/bcj.2015.39] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 04/17/2015] [Indexed: 01/21/2023] Open
Abstract
Although several new therapeutic approaches have improved outcomes in the treatment of hematologic malignancies, unmet need persists in acute myeloid leukemia (AML), multiple myeloma (MM) and non-Hodgkin's lymphoma. Here we describe the proteomic identification of a novel cancer target, SAIL (Surface Antigen In Leukemia), whose expression is observed in AML, MM, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While SAIL is widely expressed in CLL, AML, MM, DLBCL and FL patient samples, expression in cancer cell lines is mostly limited to cells of AML origin. We evaluated the antitumor activity of anti-SAIL monoclonal antibodies, 7-1C and 67-7A, conjugated to monomethyl auristatin F. Following internalization, anti-SAIL antibody–drug conjugates (ADCs) exhibited subnanomolar IC50 values against AML cell lines in vitro. In pharmacology studies employing AML cell line xenografts, anti-SAIL ADCs resulted in significant tumor growth inhibition. The restricted expression profile of this target in normal tissues, the high prevalence in different types of hematologic cancers and the observed preclinical activity support the clinical development of SAIL-targeted ADCs.
Collapse
Affiliation(s)
- S Y Kim
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - J-W Theunissen
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - J Balibalos
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - S Liao-Chan
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - M C Babcock
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - T Wong
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - B Cairns
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - D Gonzalez
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - E H van der Horst
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - M Perez
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - Z Levashova
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - L Chinn
- Department of Preclinical Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - J A D'Alessio
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - M Flory
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - A Bermudez
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - D Y Jackson
- Department of Chemistry, Igenica Biotherapeutics, Burlingame, CA, USA
| | - E Ha
- Department of Chemistry, Igenica Biotherapeutics, Burlingame, CA, USA
| | - J Monteon
- Department of Process Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - M F Bruhns
- Department of Process Development, Igenica Biotherapeutics, Burlingame, CA, USA
| | - G Chen
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| | - T-S Migone
- Department of Biology, Igenica Biotherapeutics, Burlingame, CA, USA
| |
Collapse
|